Biotech newsletters usually hinge on one question – can the editor identify an FDA event before the broader market reacts. This Ray Blanco review focuses on that exact claim, looking at FDA Profit Alert, the Flash Approval Indicator, and how the service is presented to readers who want exposure to biotech stock moves tied to drug decisions. The core pitch is simple: spot the approval window early, then act before the headline reaches everyone else.
2
The service is framed around biotech as a sector with unusually strong event-driven momentum. The argument is that health care innovation keeps attracting capital because demand tied to treatment and cancer care does not fade in the way consumer tech trends sometimes do.
The sales narrative leans heavily on catalysts. In biotech, a single FDA ruling can reset expectations fast, and timing matters more than broad sector enthusiasm. Get in too early and capital can sit idle. Arrive after the announcement and the easiest move may already be gone.
That is where Ray Blanco places his Flash Approval Indicator. According to the presentation, the tool attempts to flag unusual activity ahead of major FDA announcements, with historical testing used as support for the claim. From our experience covering speculative markets, any indicator tied to one event type should be judged by consistency and by how clearly entry and exit timing are explained.
The promotion says that once the indicator starts flashing, it points to a small biotech company that may be close to a sharp upward move. The idea is that subscribers still have a window to enter before the market fully prices in the decision.
The broader promise is straightforward. If the indicator is right, one approval call could open the door to a string of outsized winners over time through FDA Profit Alert research.
Ray Blanco is presented as the editor behind Technology Profits Confidential, Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. He has been with Seven Figure Publishing since 2010.
The source also notes that in 2019, his closed positions in Technology Profits Confidential beat the S&P 500 by 50%. That figure is part of the service background, though readers should still separate marketing claims from a repeatable process, especially in a volatile investment niche.
| Metric | Score | Number of Reviews |
|---|---|---|
| Overall satisfaction | 4.9 out of 5 | 71 |
| Written comments | Included | 57 |
| Likelihood to recommend | 4.9 out of 5 | 71 |
| Recommend to family and friends | 4.8591547 out of 5 | Not stated |
When we checked how these medical review pages usually present trust signals, the more useful details were the written themes rather than the headline number. In Dr. Ray Blanco’s case, the comments consistently point to a physician who is viewed as knowledgeable and careful during appointments.
Dr. Ray Blanco is identified as a head and neck surgical oncology specialist, with general surgery also listed among his specialties. Public medical profile summaries also point to expertise in surgical care for head and neck Cancer, including tumor-focused treatment in that region.
Publicly available condition summaries also suggest experience with related head and neck malignancies beyond the most frequently cited cases, though the clearest recurring references are still oral cancer and laryngeal cancer.
For people researching the doctor rather than the newsletter editor, that distinction is important. The medical profile relates to surgical oncology care, while FDA Profit Alert is a publishing service tied to biotech investment research.
Based on publicly available doctor-profile information, Dr. Ray Blanco is listed as accepting new patients. We checked the same type of profile sources for location details, but the article source used here does not provide a verified street address or full practice location.
That means the acceptance status appears clearer than the location data in the materials tied to this ray blanco review. Anyone trying to confirm where he practices would need to rely on the latest medical directory listing or the office contact details shown on the provider page.
Subscribers are told to expect fresh issues and trade alerts on a near-weekly basis. The weekly note is paired with email updates whenever Ray Blanco says the indicator detects a new FDA setup. A separate alert is also promised when it is time to close a position.
The package is clearly designed to make the service feel active rather than passive. In practical terms, that means subscribers are being sold an alert-driven workflow, similar to how traders watch for a stock trigger or a PayPal payment confirmation before taking the next step.
At the time reflected in the source material, there were 2 subscription choices for FDA Profit Alert.
The guarantee is called the FDA Ironclad Profit Guarantee. The yearly plan is the one tied to the full 12-month policy.
Under that offer, Ray Blanco says subscribers will get the chance at a minimum of 20 winners of 500% or more during the year. If that opportunity set does not materialize, the remedy described is lifetime access to the service at no extra cost. As with any newsletter guarantee, the wording centers on the chance to participate, not on guaranteed portfolio outcomes.
The closing argument behind FDA Profit Alert is that FDA approvals can move small biotech stocks sharply, and that ordinary investors usually see those moves only after the market has already repriced them. The Flash Approval Indicator is sold as the edge that solves that timing gap.
The source also claims the indicator had recently shown a strong spike for one company, suggesting an approval announcement could be close.
New members are told they will quickly receive a report covering that initial trade setup and the steps needed to follow it. After that, the service is positioned as an ongoing FDA-monitoring product, with Ray Blanco scanning the biotech space daily for fresh approval signals.
Overall, the newsletter side of this ray blanco review comes down to a familiar proposition in speculative research. If the underlying signal is timely and the exits are disciplined, event-based biotech alerts can attract attention. If the signal is inconsistent, the story loses force quickly. The doctor side of the same search term is much clearer, with public patient reviews pointing to high satisfaction, strong recommendation scores, and a focus on head and neck cancer care.
News about digital currencies, fintech trends and financial innovations
CoinSpot.io - the largest Runet resource about digital currencies, fintech trends and financial innovations. We talk about technologies, startups and entrepreneurs shaping the face of the financial world. Venture investments, p2p and digital technologies, cryptocurrencies, analytics and reviews - everything you need to know to stay in trend and earn.
Full or partial use of site materials is allowed only with the written permission of the editorial office, and a link to the source is mandatory!
Reviews (3)
Ray Blanco’s FDA Profit Alert is a joke—his Flash Approval Indicator is just a flashy gimmick that doesn’t deliver real results.
Ray Blanco’s FDA Profit Alert hinges on the Flash Approval Indicator, claiming to predict FDA decisions ahead of the market. However, relying on a single event-driven signal in the volatile biotech sector is risky. Without transparent entry and exit strategies, this approach seems more speculative than strategic. Investors should be cautious of such oversimplified methods.
I can’t believe I fell for this so-called “FDA Profit Alert” scam. Ray Blanco’s flashy “Flash Approval Indicator” was nothing but a gimmick, leading me to invest in biotech stocks that tanked. The promises of early FDA event detection were empty, and now I’m left with significant losses. It’s infuriating how these so-called experts exploit investors with misleading claims.